SCHEMBL832925

SCHEMBL832925

CCOC(=O)c1c(Cl)cc(-c2ccc(Cl)cc2)nc1C(F)(F)F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
ALPL P05186 1/20 0.50
SMN1; SMN2 Q16637 4/20 0.49
KDM4E B2RXH2 2/20 0.49
HPGD P15428 2/20 0.49
MAPT P10636 4/20 0.47
MEN1 O00255 1/20 0.47
POLB P06746 1/20 0.47
XBP1 P17861 1/20 0.47
KMT2A Q03164 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
TARBP2 Q15633 1/20 0.44
GABRA2 P47869 3/20 0.44
GABRB2 P47870 3/20 0.44
PRKCZ Q05513 1/20 0.44
TRPM8 Q7Z2W7 1/20 0.44
ALOX5 P09917 2/20 0.43
TP53 P04637 1/20 0.43
MDM2 Q00987 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL830313 0.84 ALDH1A1 (0.47) ALDH1A1L3MBTL1ALPLSMN1; SMN2KDM4E
SCHEMBL10363867 0.81 KDM4E (0.46) ALDH1A1L3MBTL1SMN1; SMN2KDM4EHPGD
SCHEMBL16965482 0.81 KDM4E (0.46) ALDH1A1L3MBTL1SMN1; SMN2KDM4EHPGD
SCHEMBL10364605 0.79 ALDH1A1 (0.44) ALDH1A1L3MBTL1SMN1; SMN2KDM4EHPGD
SCHEMBL9775609 0.77 SMN1; SMN2 (0.48) ALDH1A1L3MBTL1SMN1; SMN2KDM4EHPGD
SCHEMBL831044 0.75 ALDH1A1 (0.50) ALDH1A1L3MBTL1SMN1; SMN2KDM4EHPGD
SCHEMBL22712490 0.75 ALDH1A1 (0.55) ALDH1A1L3MBTL1ALPLSMN1; SMN2KDM4E
SCHEMBL29410002 0.75 ALDH1A1 (0.55) ALDH1A1L3MBTL1ALPLSMN1; SMN2KDM4E
SCHEMBL831460 0.74 ALDH1A1 (0.49) ALDH1A1L3MBTL1SMN1; SMN2KDM4EHPGD
SCHEMBL829828 0.73 SMN1; SMN2 (0.41) ALDH1A1L3MBTL1ALPLSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143411-B2 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2012-03-27 US disclosed
US-8143411-B2 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2012-03-27 US disclosed
US-8143411-B2 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2012-03-27 US disclosed
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2010-09-16 US disclosed
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2010-09-16 US disclosed
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2010-09-16 US disclosed
WO-2009033561-A1 SUBSTITUTED 6-PHEYLNICOTINIC ACIDS AND THE USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use SLC5A6, FABP3, NAPRT ALDH1A1 1238/4885L3MBTL1 823/4885ALPL 783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.